Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer - A Southwest Oncology Group study

Joshua O. Atiba; Stephanie J. Green; Harry E. Hynes; C. Kent Osborne; Thomas P. Miller; Mark Davidner

doi:10.1007/BF00874442

Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer - A Southwest Oncology Group study

Joshua O. Atiba, Stephanie J. Green, Harry E. Hynes, C. Kent Osborne, Thomas P. Miller, Mark Davidner

English

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

The Southwest Oncology Group studied the response rate and toxicity of mitoxantrone (7.5 or 10 mg/m² to 12.0 mg/m²) and cis-platinum (100 mg/m²) in 30 patients with advanced breast cancer as second-line therapy. There were 2 partial responses in 29 eligible patients. Toxicity was considerable, with 27 patients having grade 3 or 4 toxicity. Grade 3-4 toxicity included vomiting, thrombocytopenia, granulocytopenia, leukopenia and anemia. The combination of mitoxantrone plus cis-platinum has minimal activity as second-line therapy in metastatic breast cancer.

Original language	English (US)
Pages (from-to)	129-132
Number of pages	4
Journal	Investigational New Drugs
Volume	12
Issue number	2
DOIs	https://doi.org/10.1007/BF00874442
State	Published - Jun 1994

Keywords

breast cancer
cis-platinum
mitoxantrone
phase I-II trial

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00874442

Cite this

@article{b2ef629f2e194fb79aaed2e9bcc441e8,

title = "Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer - A Southwest Oncology Group study",

abstract = "The Southwest Oncology Group studied the response rate and toxicity of mitoxantrone (7.5 or 10 mg/m2 to 12.0 mg/m2) and cis-platinum (100 mg/m2) in 30 patients with advanced breast cancer as second-line therapy. There were 2 partial responses in 29 eligible patients. Toxicity was considerable, with 27 patients having grade 3 or 4 toxicity. Grade 3-4 toxicity included vomiting, thrombocytopenia, granulocytopenia, leukopenia and anemia. The combination of mitoxantrone plus cis-platinum has minimal activity as second-line therapy in metastatic breast cancer.",

keywords = "breast cancer, cis-platinum, mitoxantrone, phase I-II trial",

author = "Atiba, {Joshua O.} and Green, {Stephanie J.} and Hynes, {Harry E.} and Osborne, {C. Kent} and Miller, {Thomas P.} and Mark Davidner",

year = "1994",

month = jun,

doi = "10.1007/BF00874442",

language = "English (US)",

volume = "12",

pages = "129--132",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "2",

}

TY - JOUR

T1 - Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer - A Southwest Oncology Group study

AU - Atiba, Joshua O.

AU - Green, Stephanie J.

AU - Hynes, Harry E.

AU - Osborne, C. Kent

AU - Miller, Thomas P.

AU - Davidner, Mark

PY - 1994/6

Y1 - 1994/6

N2 - The Southwest Oncology Group studied the response rate and toxicity of mitoxantrone (7.5 or 10 mg/m2 to 12.0 mg/m2) and cis-platinum (100 mg/m2) in 30 patients with advanced breast cancer as second-line therapy. There were 2 partial responses in 29 eligible patients. Toxicity was considerable, with 27 patients having grade 3 or 4 toxicity. Grade 3-4 toxicity included vomiting, thrombocytopenia, granulocytopenia, leukopenia and anemia. The combination of mitoxantrone plus cis-platinum has minimal activity as second-line therapy in metastatic breast cancer.

AB - The Southwest Oncology Group studied the response rate and toxicity of mitoxantrone (7.5 or 10 mg/m2 to 12.0 mg/m2) and cis-platinum (100 mg/m2) in 30 patients with advanced breast cancer as second-line therapy. There were 2 partial responses in 29 eligible patients. Toxicity was considerable, with 27 patients having grade 3 or 4 toxicity. Grade 3-4 toxicity included vomiting, thrombocytopenia, granulocytopenia, leukopenia and anemia. The combination of mitoxantrone plus cis-platinum has minimal activity as second-line therapy in metastatic breast cancer.

KW - breast cancer

KW - cis-platinum

KW - mitoxantrone

KW - phase I-II trial

UR - http://www.scopus.com/inward/record.url?scp=0027994879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027994879&partnerID=8YFLogxK

U2 - 10.1007/BF00874442

DO - 10.1007/BF00874442

M3 - Article

C2 - 7860229

AN - SCOPUS:0027994879

SN - 0167-6997

VL - 12

SP - 129

EP - 132

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 2

ER -

Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer - A Southwest Oncology Group study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this